EFNB2 and neoplasm: Successful approaches will use therapies that 1) mimic the ephrin-B2 ligand and stimulate tumour suppressive signaling pathways, 2) cause internalisation and degradation of EphB4 preventing further ligand-independent signaling that is tumour promoting and 3) can block further de novo EphB4 production.